Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eixxCfbwocfadsntfPbJ

January 30, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
  • Study: 18F-ISO-1 PET effective at imaging cycling cancer cells
    PET scans using 18F-ISO-1 in patients with newly diagnosed primary breast cancer, head and neck cancer or lymphoma showed significant correlation between uptake of tumor Ki-67, a marker for cancer cell proliferation, and 18F-ISO-1 in terms of tumor-to-muscle activity ratios and maximum standard uptake value, according to a study in the Journal of Nuclear Medicine. "The high correlation of tumor-to-muscle ratio with Ki-67 scores indicates that F18-ISO-1 may provide an imaging alternative to biopsy specimens for obtaining this measurement," researchers said. The method may also be useful in identifying patients likely to respond to treatments against cycling cancer cells, they added. MolecularImaging.net (1/28) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Experts give advice on how to boost awareness about contrast agents
    Patients have concerns about the use of contrast agents in their tests, and it is the task of radiologists to help them understand the reasons behind and procedures involved with the use of the agents, experts say. Patient discussions about the benefits and risks of contrast agents before use are very important, said Dr. Lawrence Marks from the University of North Carolina at Chapel Hill School of Medicine. Exploring all non-contrast options is best, said Dr. Jeffrey Kanne from the University of Wisconsin School of Medicine and Public Health, but if it is absolutely necessary to use contrast agents, patients should repeat the information given them back to the radiologist to show they really understand. Diagnostic Imaging (1/29) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Endocyte touts positive Phase 0 results for EC0652
    Endocyte said a Phase 0 study showed its EC0652, an imaging agent for prostate-specific membrane antigen, is safe and effective at targeting diseased cells. Based on the results, the company said it plans to advance the development of EC0652 and its therapeutic agent EC1069. Endocyte said it is looking to file an investigational new drug application for EC1069 by year's end. RTT News/News release (1/29) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • AdvaMed, others redouble efforts to repeal 2.3% device tax
    The Advanced Medical Technology Association has joined forces with two other industry groups to press Congress to repeal the 2.3% medical device tax as the first payment due date arrived this week. "This tax is already resulting in layoffs, reduced investments in R&D and delays in significant capital improvements. We urge Congress to act swiftly and repeal this job-killing, innovation-destroying, anti-competitive tax," AdvaMed President and CEO Stephen Ubl said. MassDevice.com (Boston) (1/29) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Russia claims desire to rein in HEU use
    U.S. officials are increasingly confident that Russia will hold to its plan to limit the use of highly enriched uranium in manufacturing medical isotopes, sources familiar with the matter said. "We have no reason to doubt the Russians' commitment to work toward the conversion of their [medical isotope] production process from HEU targets to LEU targets as they have stated at recent international conferences," said Parrish Staples, director of European and African threat reduction for the National Nuclear Security Administration. This confidence in Russia may delay Congress from implementing a ban on HEU imports. However, Nuclear Proliferation Prevention Project coordinator Alan Kuperman said the HEU ban is still needed. Global Security Newswire (1/29) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • Restricting biosimilars could cut expected savings on drug costs
    The savings considered under the Affordable Care Act could potentially drop as drugmakers push state legislatures to restrict substitution of biosimilar drugs for branded biologic therapies. Bills under consideration would require patient consent and doctor notification before a biosimilar may be substituted and would mandate that only drugs deemed interchangeable, and not just similar, by the FDA could be given instead. The New York Times (tiered subscription model) (1/28) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Senator's bill to target physician shortage in U.S.
    Sen. Bernie Sanders, I-Vt., said Tuesday he would introduce a bill to address the shortage of primary care physicians before the implementation of the Affordable Care Act's individual insurance mandate, insurance exchanges and Medicaid expansion next year. The bill would include funding to expand community health centers and the National Health Service Corps. The shortage "has been accentuated by the ACA and 30 million more people getting insurance, so we just got to make sure there is a place for them to go," Sanders said. Modern Healthcare (subscription required) (1/29) , The Washington Times (1/29) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
  From SNMMI 
  • SNMMI 2013 Annual Meeting online meeting planner now available!
    Visit the Meeting Planner and see what's happening at this year's Annual Meeting. With more than 100 CE sessions available, you'll quickly understand why thousands of professional attendees have called it the premier educational and networking event in nuclear medicine and molecular imaging. Register today. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
Resentment is like taking poison and waiting for the other person to die."
--Malachy McCourt,
Irish-American actor, writer and politician


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information